Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study
| Autor: | Madison Macht, Ellen L. Burnham, Christina A. Meadows, Marc Moss, Jeanette Gaydos, Amanda R. Stream, Alexander B. Benson, Brendan J. Clark, Todd M. Bull |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty ARDS Growth Differentiation Factor 15 Acute respiratory distress 030204 cardiovascular system & hematology Pulmonary Artery Critical Care and Intensive Care Medicine growth differentiation factor-15 03 medical and health sciences risk prediction 0302 clinical medicine Internal medicine medicine Humans In patient 030212 general & internal medicine Intensive care medicine Retrospective Studies Respiratory Distress Syndrome Acute respiratory distress syndrome business.industry Research Retrospective cohort study Middle Aged medicine.disease Prognosis 3. Good health pulmonary vascular dysfunction Catheterization Swan-Ganz embryonic structures Commentary Biomarker (medicine) Fluid Therapy Female GDF15 business Biomarkers |
| Zdroj: | Critical Care |
| ISSN: | 1466-609X |
| Popis: | Introduction We sought to determine whether higher levels of the novel biomarker growth differentiation factor-15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). Methods We conducted a retrospective cohort study in patients enrolled in the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment (FACT) Trial. Patients enrolled in the FACT Trial who received a pulmonary artery catheter (PAC), had plasma available from the same study day and sufficient hemodynamic data to determine the presence of PVD were included. Logistic regression was used to determine the association between GDF-15 level and 60-day mortality. Results Of the 513 patients enrolled in the FACT Trial assigned to receive a PAC, 400 were included in this analysis. Mortality at 60 days was significantly higher in patients whose GDF-15 levels were in the third (28%) or fourth (49%) quartile when compared to patients with GDF-15 levels in the first quartile (12%) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink